TSE:GUD FY2027 EPS Increased by Raymond James Financial

Knight Therapeutics Inc. (TSE:GUD) – Research analysts at Raymond James Financial boosted their FY2027 earnings per share estimates for shares of Knight Therapeutics in a report released on Wednesday, June 18th. Raymond James Financial analyst M. Freeman now anticipates that the company will post earnings of $0.17 per share for the year, up from their previous forecast of $0.15. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James Financial also issued estimates for Knight Therapeutics’ FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.35 EPS.

A number of other research analysts have also recently commented on the company. Stifel Nicolaus upped their price objective on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a report on Tuesday, March 25th. Canaccord Genuity Group set a C$6.50 target price on Knight Therapeutics and gave the company a “buy” rating in a research report on Friday, May 9th. Finally, Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. Two analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Knight Therapeutics currently has an average rating of “Strong Buy” and an average target price of C$7.15.

Knight Therapeutics Trading Down 0.2%

GUD opened at C$5.80 on Monday. Knight Therapeutics has a one year low of C$5.09 and a one year high of C$6.45. The stock has a market capitalization of C$586.67 million, a PE ratio of -19.36, a P/E/G ratio of -1,013.50 and a beta of 0.50. The business’s 50 day moving average price is C$5.88 and its 200 day moving average price is C$5.71. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.